imm8k-022208.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 22,
2008
IMMTECH
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
(State
or Other Jurisdiction of Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
One
North End Avenue
New
York, New York 10282
(Address
of Principal Executive Offices, including Zip Code)
(212)
791-2911
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
8.01 Other
Events.
On
February 22, 2008, Immtech Pharmaceuticals, Inc. (the “Company”) (Amex: IMM)
announced that it had received reports of abnormal kidney function that resulted
in the hospitalization of several volunteers who participated in the Company’s
ongoing safety study for pafuramidine (DB289), an investigational
therapy. The pafuramidine development program had been on clinical
hold since late December 2007 due to earlier findings of abnormal laboratory
values in the liver function of some safety study volunteers.
The
Company has received recommendations from the Data Safety Monitoring Board and
the oversight entities for the Company’s African sleeping sickness grant and
Pneumocystis pneumonia study. After consulting with these parties and assessing
the potential benefits and risks and resources required for the
continuation of the pafuramidine development program, the Company has chosen to
discontinue the program. The Company has notified its licensing
partners and the U.S. Food and Drug Administration (the “FDA”).
The
Company’s first concern has been, and will be, the safety of volunteers and
patients. It immediately arranged for all volunteers in the safety
study to have follow-up examinations and any necessary laboratory
testing. Immtech also notified all investigators who have enrolled
volunteers or patients in any pafuramidine clinical studies during the prior 12
months and provided them with instructions related to any necessary
follow-up.
The
Company is currently developing a plan to close out the pafuramidine development
program, which it expects will take 6 to 8 months to complete. In
addition, the Company is working with its consultants and oversight groups to
review the program in order to gain insight that can be applied to the
development of other dicationic compounds. The Company has gained
much information from the program that it believes can be used to guide existing
and future drug development programs.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Date:
February 22, 2008
|
IMMTECH
PHARMACEUTICALS, INC.
|
| |
|
|
|
|
|
|
Eric
L. Sorkin
Chairman,
Chief Executive Officer and
President
|